Literature DB >> 8834477

Connexins and E-cadherin are differentially expressed during trophoblast invasion and placenta differentiation in the rat.

B Reuss1, P Hellmann, E Dahl, O Traub, A Butterweck, R Grümmer, E Winterhager.   

Abstract

We have characterized the spatial and temporal expression pattern of six different connexin genes and E-cadherin during trophectoderm development in the rat. During the initial phase of trophoblast invasion at 6 days postcoitum (dpc), the trophoblast expressed E-cadherin but no connexin expression could be observed. With progressing invasion of the polar trophoblast into the maternal decidua, from 7 dpc onwards E-cadherin expression in the ectoplacental cone cells was lost and was now restricted to the extraembryonic ectoderm. In the ectoplacental cone and extraembryonic ectoderm instead connexin31 mRNA and protein could be found. This pattern was maintained up to day 10 postcoitum. The start of labyrinthine trophoblast differentiation from day 11 postcoitum onwards was characterized by persisting expression of E-cadherin in the extraembryonic ectoderm and its derivative, the chorionic plate. In addition to E-cadherin, from 10 dpc onwards, connexin26 started to be expressed in the chorionic plate, and both molecules remained coexpressed in the labyrinthine trophoblast of the mature placenta. During this differentiation process connexin31 remained expressed mainly in the proliferating spongiotrophoblast. From day 14 postcoitum onwards, the expression of connexin31 in the spongiotrophoblastic cells decreased, and in parallel they started to express connexin43. The trophoblastic giant cells, first characterized by connexin31, lost all of the investigated connexins during midgestation on day 12 postcoitum but started to express connexin43 from day 18 postcoitum onwards. Our studies suggest that loss of E-cadherin and induction of connexin31 expression is correlated with the proliferative and invasive stages of the ectoplacental cone, whereas appearance of connexin26, E-cadherin and connexin43 reflects the switch to the differentiated phenotypes of the mature placenta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834477     DOI: 10.1002/(SICI)1097-0177(199602)205:2<172::AID-AJA8>3.0.CO;2-F

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  6 in total

Review 1.  Role of placenta in preeclampsia.

Authors:  Leslie Myatt
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.

Authors:  Kun Xia; Hong Ma; Hui Xiong; Qian Pan; Liangqun Huang; Danling Wang; Zhuohua Zhang
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

3.  Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction.

Authors:  Vicki Plaks; Julie Rinkenberger; Joanne Dai; Margaret Flannery; Malin Sund; Keizo Kanasaki; Wei Ni; Raghu Kalluri; Zena Werb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

4.  Protocadherin 12 deficiency alters morphogenesis and transcriptional profile of the placenta.

Authors:  Christine Rampon; Stéphanie Bouillot; Adriana Climescu-Haulica; Marie-Hélène Prandini; Francine Cand; Yves Vandenbrouck; Philippe Huber
Journal:  Physiol Genomics       Date:  2008-05-13       Impact factor: 3.107

5.  Down-regulation of the transcription factor snail in the placentas of patients with preeclampsia and in a rat model of preeclampsia.

Authors:  Larisa Fedorova; Cara Gatto-Weis; Sleiman Smaili; Nauman Khurshid; Joseph I Shapiro; Deepak Malhotra; Terrence Horrigan
Journal:  Reprod Biol Endocrinol       Date:  2012-02-23       Impact factor: 5.211

6.  Transplacental uptake of glucose is decreased in embryonic lethal connexin26-deficient mice.

Authors:  H D Gabriel; D Jung; C Bützler; A Temme; O Traub; E Winterhager; K Willecke
Journal:  J Cell Biol       Date:  1998-03-23       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.